spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  anthracycline 

 HSMN NewsFeed - 18 Sep 2024
Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of 420mg Strength of HERCESSI(TM) (trastuzumab-strf), a biosimilar to Herceptin(R) (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer
Biopharmaceuticals Generics Oncology FDA
 HSMN NewsFeed - 23 Jun 2022
CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Jun 2021
FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Apr 2021
GLOBAL Sarcoma Therapy Now Approved for Australian Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Aug 2020
NBE-Therapeutics Appoints Erich Schlick as Chairman of the Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Jun 2020
CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin
Biopharmaceuticals Oncology Neurology FDA
 HSMN NewsFeed - 20 Apr 2020
Moleculin Announces Agreement with ImQuest Biosciences to Expand Coronavirus Testing
Biopharmaceuticals
 HSMN NewsFeed - 26 Nov 2019
CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 19 Nov 2019
CNS Pharmaceuticals Acquired Worldwide Rights for Brain Cancer Drug from Houston Pharmaceuticals
Biopharmaceuticals Licensing
 HSMN NewsFeed - 18 Jan 2019
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Sep 2018
Cumberland Pharmaceuticals Announces Senior Music Industry Executive Joins Its Board Of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Aug 2018
Cumberland Pharmaceuticals Appoints New Senior Executive
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jul 2018
Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI(R) (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Apr 2018
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO(R) (fosnetupitant/ palonosetron) in the United States
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Apr 2018
Cumberland Pharmaceuticals Expands into Oncology Support
Biopharmaceuticals Oncology Licensing Distribution
 HSMN NewsFeed - 10 Jan 2018
Morphotek Announces FDA Acceptance Of Investigational New Drug Application For Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Sep 2017
Cumberland Pharmaceuticals Launches Promotion of Totect(R) in The U.S. for Emergency Oncology Intervention
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 22 Mar 2017
Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Nov 2016
Eisai Welcomes Positive NICE recommendation for Halaven(R) (eribulin) for Patients with Locally Advanced or Metastatic Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Sep 2016
Eisai Bewildered as German Institute for Quality and Efficiency in Health Care (IQWIG) Fails to Recognise Additional Benefit of Halaven(R) (eribulin) in the Treatment of Advanced Liposarcoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Aug 2016
Sunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Aug 2016
Heron Therapeutics Announces U.S. FDA Approval of SUSTOL(R) (granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jan 2016
FDA Approves Eisai's Halaven(R) (eribulin mesylate) Injection for the Treatment of Patients with Advanced Liposarcoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Mar 2015
Hong Kong Authority Approves Abraxane(R) as First-Line Treatment For Late-Stage Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Feb 2015
Topline Results of Phase 3 Trial Show Eribulin Mesylate Injection Meets Primary Endpoint of Overall Survival in Advanced Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Feb 2015
Genentech’s Phase III Study of Gazyva(R) Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Feb 2015
U.S. FDA Grants Priority Review for YONDELIS(R) (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Jan 2015
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Oct 2014
FDA Approves AKYNZEO(R) (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Sep 2014
CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And Commercialize PIXUVRI(R)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 25 Jul 2014
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR(R) (sorafenib) in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Jan 2014
PIXUVRI(R) (pixantrone) Receives Positive Final Appraisal Determination from NICE
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Dec 2013
Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI(R) (pixantrone) in Germany
Biopharmaceuticals Oncology Reimbursement
 HSMN NewsFeed - 2 Dec 2013
Celldex Therapeutics Initiates METRIC, an Accelerated Approval Study of Glembatumumab Vedotin in Patients with Triple Negative Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Oct 2013
Second Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Sep 2013
U.S. Food and Drug Administration Approves ABRAXANE(R) in Combination with Gemcitabine as First-Line Treatment of Patients with Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Aug 2013
Market Access Granted in France for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Jul 2013
Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Jul 2013
Cell Therapeutics Provides Reimbursement Update for the UK for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Reimbursement
 HSMN NewsFeed - 2 Jul 2013
FDA Grants Genentech’s Perjeta Regimen Priority Review for Use Before Surgery in HER2-Positive Early Stage Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Mar 2013
Clinigen Group plc Acquires Oncology Support Therapy Cardioxane(R) from a World-Leading Pharmaceutical Company
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 12 Oct 2012
FDA Approves ABRAXANE(R) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Sep 2012
Cell Therapeutics Announces European Launch Of Pixuvri(R) For Treatment Of Adult Patients With Multiply Relapsed Or Refractory Aggressive Non-Hodgkin B-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jun 2012
New Data From Phase III Study Showed That People With HER2-Positive Metastatic Breast Cancer Lived Longer With Genentech’s Perjeta
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jun 2012
Cell Therapeutics Appoints New Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 31 May 2012
Cell Therapeutics' Pixuvri(R) Phase 3 Clinical Trial Results Published in The Lancet Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Mar 2012
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jan 2012
Cell Therapeutics Withdraws New Drug Application for Pixuvri™ and Plans to Resubmit in 2012
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Sep 2011
Independent Radiology Assessment Panel Results Confirm Statistical Significance of Response and Progression Endpoints of Cell Therapeutics' Pixantrone PIX301 Pivotal Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jul 2011
Pertuzumab Combined With Herceptin and Chemotherapy Significantly Extended the Time People With HER2-Positive Metastatic Breast Cancer Lived Without Their Disease Getting Worse
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Apr 2011
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Feb 2011
FDA Grants Genentech a Hearing on Avastin’s Use for Metastatic Breast Cancer in the United States
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Feb 2011
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Feb 2011
Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jan 2011
APP Pharmaceuticals Announces Agreement with Teva Pharmaceuticals to Manufacture and Market Gemcitabine HCI for Injection
Biopharmaceuticals Licensing Oncology
 HSMN NewsFeed - 16 Dec 2010
Genentech Provides Update on Avastin for Metastatic Breast Cancer Following Reviews in Europe and the United States
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Dec 2010
Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate of Complete Tumor Disappearance in Study of Women With Newly Diagnosed, Early-Stage HER2-Positive Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Dec 2010
Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Nov 2010
European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Nov 2010
FDA Approves Eisai’s Halaven(TM) (Eribulin Mesylate) Injection for Treatment of Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Oct 2010
Celgene Completes Acquisition of Abraxis
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Sep 2010
Cell Therapeutics to Appeal FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Aug 2010
Genentech Provides Update on FDA Application for T-DM1
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Jul 2010
Abraxis BioScience and Specialised Therapeutics Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Jul 2010
ABRAXANE(R) Approved for Marketing in Japan for Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Jul 2010
Genentech Submits Application to FDA for Trastuzumab-DM1 in Previously Treated Advanced HER2-Positive Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Jun 2010
Celgene to Acquire Abraxis BioScience Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 8 Jun 2010
New ABRAXANE(R) Data Demonstrates Potential in Patients with Advanced and Malignant Melanoma, Among the Toughest Cancers to Treat
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Apr 2010
Genentech Submits Supplemental Application to FDA for Herceptin in Advanced HER2-Positive Stomach Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Apr 2010
CTI Receives Complete Response Letter from the FDA for Pixantrone NDA; CTI to File for Expanded Access for Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 Mar 2010
Eisai Submits Marketing Authorisation Application for Approval of Eribulin Mesylate in Europe, Based on Significant Overall Survival in Late Stage Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Mar 2010
ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Feb 2010
Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jan 2010
GSK's TYKERB(R) Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Dec 2009
European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Dec 2009
Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2009
Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Nov 2009
Genentech Submits Supplemental Applications to FDA for Avastin Combined with Commonly Used Chemotherapies for Women with Advanced Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Nov 2009
ABRAXANE(R) Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Oct 2009
Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
Biopharmacetuicals Onocology
 HSMN NewsFeed - 29 Sep 2009
Cell Therapeutics Applies for European Orphan Drug Designation for Pixantrone in Aggressive Non-Hodgkin's Lymphoma (NHL)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Sep 2009
Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Aug 2009
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Aug 2009
APP Pharmaceuticals Receives Approval for Idarubicin HCI Injection
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 3 Aug 2009
Results from a Phase 2 Study of ABRAXANE(R) In Combination With Carboplatin Show Clinical Activity in the First Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 May 2009
FDA Grants Full Approval for SPRYCEL (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec*
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 May 2009
FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 May 2009
Pixantrone Now Available in Europe on a Named-Patient Basis
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Mar 2009
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Mar 2009
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 18 Feb 2009
Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Feb 2009
Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Feb 2009
Abraxis BioScience Launches ABRAXANE in Germany
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jan 2009
Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Dec 2008
Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Nov 2008
Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival In Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Nov 2008
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Oct 2008
Abraxis BioScience and Specialised Therapeutics Australia Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in Australia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Sep 2008
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Sep 2008
Amrubicin Receives FDA Fast Track Designation for the Treatment of Small Cell Lung Cancer after First-Line Chemotherapy
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 5 Aug 2008
Craig W. Philips Takes Helm at CTI
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jun 2008
ABRAXANE(R) in Combination with Trastuzumab and Carboplatin Evaluated as First-Line Treatment for Patients with HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2008
Combination Therapy of Solvent-Free ABRAXANE(R) and the Targeted Therapy Bevacizumab Evaluated as First-Line Treatment for Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2008
New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Apr 2008
Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 23 Apr 2008
Abraxis BioScience Reports Promising Clinical Data in Advanced Pancreatic Cancer Using a Combination of nab-Paclitaxel (ABRAXANE(R)) and Gemcitabine (Gemzar(R))
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2008
Amrubicin is Designated as an Orphan Medicinal Product by the European Commission for the Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 9 Apr 2008
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Mar 2008
Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Mar 2008
Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Mar 2008
Abraxis Bioscience Announces Filing of Marketing Application in Japan for ABRAXANE in the Treatment of Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Feb 2008
Abraxis Bioscience Establishes Global Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jan 2008
Abraxis Receives Approval from EU Commission to Market ABRAXANE for Metastatic Breast Cancer in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Jan 2008
Callisto Pharmaceuticals Amends and Restates Atiprimod License Agreement with Genzyme
Biopharmaceuticals Licensing
 HSMN NewsFeed - 17 Dec 2007
GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Dec 2007
Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2007
Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Dec 2007
Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Nov 2007
Celgene to Acquire Pharmion for $2.9 Billion in Cash and Stock
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 9 Nov 2007
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Nov 2007
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 24 Oct 2007
Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Oct 2007
Abraxis BioScience Receives a Positive Opinion in Europe from the CHMP for the Approval of ABRAXANE for the Treatment of Metastatic Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Oct 2007
Abraxis BioScience and Biocon Limited Announce Approval of ABRAXANE in India for the Treatment of Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Oct 2007
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Oct 2007
FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Oct 2007
Abraxis Bioscience Reaches Agreement with the FDA Following Special Protocol Assessment for Phase III Trial of ABRAXANE in Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Oct 2007
Callisto Pharmaceuticals Announces Major Strategic Initiative for Guanilib in GI Disorders
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 12 Sep 2007
Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Sep 2007
EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Aug 2007
Cell Therapeutics, Inc. (CTI) Enters Agreement to Acquire Lymphoma Drug Zevalin(R) from Biogen Idec for Sales and Marketing in the United States
Biopharmaceuticals Acquisitions Oncology
 HSMN NewsFeed - 8 Aug 2007
Abraxis BioScience Announces Licensing Agreement with Biocon Limited for the Commercialization of ABRAXANE in India
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 25 Jul 2007
Cell Therapeutics, Inc. (CTI) Announces Agreement to Acquire SMi; Gains Global Rights to Brostallicin, in a New Class of Cancer Killing Agents
Biopharmaceuticals Mergers & Acquisitions Oncology
 HSMN NewsFeed - 6 Jul 2007
Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jun 2007
Barr Receives Approval for Generic VESANOID(R) Capsules, 10 mg
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 19 Jun 2007
FDA Grants Priority Review for Bristol-Myers Squibb's Investigational Oncology Treatment Ixabepilone
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Jun 2007
Callisto Pharmaceuticals Files Suit Against Former Executive Vice President for Breach of Employment Agreement, Fraud, Conversion and Related Claims
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jun 2007
Clinical Results From EntreMed's Panzem(R) NCD and Taxol(R) Breast Cancer Study Presented at ASCO
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
New Data Shows Promising Antitumor Activity with nab-paclitaxel (ABRAXANE(R)) in Combination and as a Single Agent for the Treatment of Lung and Ovarian Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Cytokinetics Announces the Presentation of Clinical Trials Data at the 2007 Annual Meeting of the American Society of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Telik Reports Results of TELCYTA(R) ASSIST-1 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
CAELYX(R) Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Glaxosmithkline Reports Positive New Data on Tykerb(R)(Lapatinib) at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Phase III Ixabepilone Study Demonstrated Significant Improvement in Progression-Free Survival in Patients With Advanced Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Study Supports Activity of GEMZAR(R) (Gemcitabine HC1 for Injection) in the Treatment of Early-Stage Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
ABRAXANE Demonstrates Longer Progression-Free Survival versus Taxotere in the Treatment of First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2007
New Data Highlighting ABRAXANE as Single Agent and in Combination for the Treatment of Breast, Lung and Ovarian Cancers to Be Presented at ASCO
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 21 May 2007
U.S. FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 17 May 2007
Cell Therapeutics, Inc. Receives FDA Special Protocol Assessment (SPA) Comments on the Design of Phase III Trial of Pixantrone in Relapsed Indolent NHL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 May 2007
Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 May 2007
Rituxan(R) Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 Apr 2007
Indevus Announces Submission of Supplemental NDA to Reintroduce VALSTAR(R) to Treat Bladder Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Mar 2007
FDA Approves TYKERB(R) (lapatinib) in Combination With Xeloda(R) (capecitabine) for the Treatment of Advanced or Metastatic Breast Cancer in Women Who Have Progressed on Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Mar 2007
Cell Therapeutics, Inc. (CTI) Files for Special Protocol Assessment (SPA) for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Jan 2007
Cephalon Comments on Study of its Leukemia Treatment Led by National Cancer Institute Cooperative Group
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jan 2007
Ortho Biotech Seeks FDA Approval for DOXIL(R) in Combination with VELCADE(R) to Treat Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Dec 2006
Dr. Geoffrey Henson to Join Callisto Pharmaceuticals
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Dec 2006
ADVENTRX Initiates CoFactor Phase II Clinical Trial in Refractory Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Dec 2006
Callisto Pharmaceuticals Files Suit Against Tapestry Pharmaceuticals for Breach of Confidential Disclosure Agreement
Biopharmaceuticals Litigation
 HSMN NewsFeed - 18 Dec 2006
Anthracyclines May Not Be for Everyone: Report From the 29th Annual San Antonio Breast Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Dec 2006
New Data On Pfizer's Aromasin and Ellence to Be Presented at San Antonio Breast Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2006
Cell Therapeutics, Inc. (CTI) Announces Pixantrone Combination Regimen Produces High Response Rates
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Abraxis BioScience to Present Data from Six Studies at San Antonio Breast Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
'Impressive' Complete Remission and 'Durable' Survival Data in Relapsed Indolent NHL Patients Identifies New Potential Registration Trial for Pixantrone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Nov 2006
Cytokinetics and GlaxoSmithKline Amend Collaboration and License Agreement
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 16 Nov 2006
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Nov 2006
Pharmion Acquires Cabrellis Pharmaceuticals, Gains Rights to Amrubicin for North America and the European Union
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 7 Nov 2006
Callisto Pharmaceuticals Initiates Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Oct 2006
Taxotere(R) Receives U.S. FDA Approval for the Treatment of Patients With Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Oct 2006
Tracy Lawhon, J.D., Joins Cabrellis Pharmaceuticals as Vice President, Regulatory Affairs and Development Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Oct 2006
Patients With HER2-Positive Breast Cancer Significantly Benefit From Addition of Xeloda to Herceptin and Taxotere Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Sep 2006
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Sep 2006
Abraxis BioScience Files Marketing Application with the European Medicines Agency for ABRAXANE in the Treatment of Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Sep 2006
Callisto Pharmaceuticals Granted Orphan Drug Designation for Atiprimod to Treat Carcinoid Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Sep 2006
Cell Therapeutics Inc. Announces Worldwide License and Co-Development Agreement for Development and Commercialization of XYOTAX(TM), an Investigational Agent for Treatment of Women with Non-small Cell Lung Cancer and Other Cancers
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 14 Sep 2006
Sara Zaknoen, M.D., Joins Cabrellis Pharmaceuticals as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jun 2006
FDA Approves SPRYCEL(TM) (dasatinib) With Two Indications
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Jun 2006
Abraxis BioScience Completes Acquisition of the AstraZeneca U.S. Branded Anesthetic and Analgesic Product Lines
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 22 Jun 2006
Analysis of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
Biopharmaceuticals
 HSMN NewsFeed - 17 May 2006
Cabrellis Pharmaceuticals Corporation Announces Corporate Launch and Founding Management Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 May 2006
Diatos Announces Acquisition of Specialty Cancer Product DaunoXome(R) from Gilead Sciences
Biopharmaceuticals Oncology Licensing
Return to NewsFeed  

 Additional items found! 106

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 106 additional stories matching:
anthracycline
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!